These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 2508120)

  • 21. Current status of thrombolysis.
    Sell JJ; Rupp FW; Telepak RJ
    West J Med; 1996; 165(1-2):53. PubMed ID: 8855686
    [No Abstract]   [Full Text] [Related]  

  • 22. Intra-arterial prourokinase effective for acute stroke therapy.
    Kruszka P
    J Fam Pract; 2000 Mar; 49(3):267-8. PubMed ID: 10735489
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombolysis with prourokinase versus urokinase: an in vitro comparison.
    Fox D; Ouriel K; Green RM; Stoughton J; Riggs P; Cimino C
    J Vasc Surg; 1996 Apr; 23(4):657-66. PubMed ID: 8627903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic effects of the prostacyclin analogue naxaprostene after oral and intraduodenal application in rabbit carotid artery thrombosis.
    Schneider J
    Agents Actions Suppl; 1992; 37():176-82. PubMed ID: 1632291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the thrombolytic effect of low urokinase concentrations.
    Matsuo O; Mihara H; Rokushima Y
    Nihon Ketsueki Gakkai Zasshi; 1976 Jun; 39(3):298-305. PubMed ID: 990007
    [No Abstract]   [Full Text] [Related]  

  • 26. [Immediate reocclusion of the infrapopliteal segment after thrombolysis in acute ischemia of the lower limb of the thrombotic nature].
    Belgrano EA; Nardella L; Palladino F
    Minerva Chir; 1995 Oct; 50(10):879-81. PubMed ID: 8684635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local thrombolytic therapy: bridging the "generation gap".
    Becker GJ
    AJR Am J Roentgenol; 1983 Feb; 140(2):403-5. PubMed ID: 6600365
    [No Abstract]   [Full Text] [Related]  

  • 29. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Rescue angioplasty].
    Rodríguez A; Pichel D; Núñez P; Arrocha A; Motta J
    Rev Med Panama; 1997 Jan; 22(1):45-56. PubMed ID: 9805094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrin-specific thrombolytic agents.
    Collen D
    Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
    Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G
    Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?].
    Kirchhof K; Sikinger M; Welzel T; Zoubaa S; Sartor K
    Rofo; 2004 Jan; 176(1):98-105. PubMed ID: 14712413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Experimental evaluation of the use of recombinant prourokinase and its immobilized forms in the treatment of postoperative fibrinoid syndrome in ophthalmology].
    Boĭko EV; Danilichev VF; Kol'tsova SV
    Biull Eksp Biol Med; 1997 Feb; 123(2):201-4. PubMed ID: 9280496
    [No Abstract]   [Full Text] [Related]  

  • 39. The matrix unloaded: aerosolized heparin or urokinase for pulmonary fibrosis.
    Idell S
    Am J Respir Crit Care Med; 2003 Dec; 168(11):1268-9. PubMed ID: 14644921
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of combination treatment with mitomycin-c and lysosome labilizers on nodular pulmonary metastases.
    Niitani H; Suzuki A; Taniguchi T; Saijo N; Kawase I; Kimura K
    Gan; 1974 Oct; 65(5):403-9. PubMed ID: 4279834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.